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and of trastuzumab (US) to trastuzumab (EU). No differ-
ences in safety and tolerability between treatments were 
noted; no subject tested positive for binding anti-bodies.
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HER2 · ABP 980 · Immunogenicity
Introduction
ABP 980 is being developed as a biosimilar to trastuzumab 
 (Herceptin®).  Herceptin® is approved for use in the United 
States (US), the European Union (EU), Japan, and much of 
the rest of the world for the treatment of metastatic breast 
cancer, early breast cancer, and metastatic gastric cancer 
[1, 2], and is the standard of care for subjects with human 
epidermal growth factor receptor 2 (HER2)-overexpressing 
breast cancer [3–5]. Trastuzumab and ABP 980 are pro-
duced by recombinant DNA technology in Chinese ham-
ster ovary (CHO) cells and both monoclonal anti-bodies 
(mAbs) bind with high affinity and specificity to the extra-
cellular domain of the HER2 [6]. Binding of trastuzumab 
to HER2 blocks receptor activation and subsequent pro-
liferation of HER2-overexpressing cells [7]. In addition to 
blocking HER2-mediated proliferation, binding of trastu-
zumab to HER2 elicits anti-body-dependent cell-mediated 
cytotoxicity (ADCC) by binding to antigens expressed on 
target cells, while the anti-body Fc domain engages Fc 
receptors (e.g., FcγRIIIa) on the surface of immune effector 
cells. This binding sequence leads to the activation of the 
effector cell, granule exocytosis, and target cell death [7].
There is increasing interest in biosimilars as alternatives 
to their respective reference products, since they can pro-
vide additional safe and efficacious treatment options for 
patients. A biosimilar is a biologic product that is similar 
Abstract 
Purpose This study compared the pharmacokinetic (PK) 
profiles of the proposed biosimilar ABP 980 and trastu-
zumab in healthy males.
Methods In this single-blind study, 157 healthy males 
were randomized 1:1:1 to a single 6  mg/kg intravenous 
infusion of ABP 980, FDA-licensed trastuzumab [trastu-
zumab (US)], or EU-authorized trastuzumab [trastuzumab 
(EU)]. Primary endpoints were area under the serum con-
centration–time curve from time 0 to infinity  (AUCinf) and 
maximum observed serum concentration (Cmax). To estab-
lish equivalence, the geometric mean ratio (GMR) and 90% 
confidence interval (CI) for Cmax and  AUCinf had to be 
within the equivalence criteria of 0.80–1.25.
Results The GMRs and 90% CIs for Cmax and  AUCinf, 
respectively, were: 1.04 (0.99–1.08) and 1.06 (1.00–1.12) 
for ABP 980 versus trastuzumab (US); 0.99 (0.95–1.03) 
and 1.00 (0.95–1.06) for ABP 980 versus trastuzumab 
(EU); and 0.96 (0.92–1.00) and 0.95 (0.90–1.01) for tras-
tuzumab (US) versus trastuzumab (EU). All comparisons 
were within the equivalence criteria of 0.80–1.25. Treat-
ment-emergent adverse events (TEAEs) were reported 
in 84.0, 75.0, and 78.2 of subjects in the ABP 980, tras-
tuzumab (US), and trastuzumab (EU) groups, respectively. 
There were no deaths or TEAEs leading to study discontin-
uation and no binding or neutralizing anti-drug anti-bodies 
were detected.
Conclusions This study demonstrated the PK similarity of 
ABP 980 to both trastuzumab (US) and trastuzumab (EU), 
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to a reference product with respect to quality, safety, and 
efficacy [8, 9]. Biosimilars are likely to have differences 
in product quality attributes owing to differences in cellu-
lar expression systems, processes, and product purification 
processes but should not have clinically meaningful differ-
ences with respect to safety, purity, and potency. Guidelines 
describing non-clinical and clinical considerations for the 
development of biosimilars, including mAbs, were issued 
by the European Medicines Agency (EMA) in 2012 and 
2014 [10, 11], and by the United States Department of 
Health and Human Services and its Food and Drug Admin-
istration (FDA) in 2014 and 2015 [12, 13].
Both FDA and EMA guidelines are similar in that each 
recommends a stepwise approach beginning with compre-
hensive analytical characterization to establish structural 
and functional similarity of the biosimilar with the refer-
ence or innovator product, followed by a pharmacokinetic 
(PK) study and a pharmacodynamic (PD) study, if a suit-
able PD marker is available, to establish equivalence. 
Finally, a comparative clinical study is conducted in a sen-
sitive population to confirm similar efficacy, safety, and 
immunogenicity of the proposed biosimilar to the reference 
product.
ABP 980 is being developed for the same indications, 
dosages, and route of administration as trastuzumab. Previ-
ous studies have shown that ABP 980 has the same amino 
acid sequence and is analytically and functionally similar 
to trastuzumab [14]. This Phase I, single-dose, PK study in 
healthy male subjects was conducted to determine the PK 
equivalence of ABP 980 to US FDA-licensed trastuzumab 
and EU-authorized trastuzumab, hereafter referred to as 
trastuzumab (US) and trastuzumab (EU), respectively. The 
secondary objectives were to compare the safety, tolerabil-
ity, and immunogenicity of ABP 980, trastuzumab (US), 
and trastuzumab (EU). Finally, to establish a scientific 
bridge between reference products sourced from the US 
and the EU, the PK equivalence between trastuzumab (US) 
and trastuzumab (EU) was evaluated.
Materials and methods
This study was conducted in accordance with the provi-
sions of the Declaration of Helsinki and in accordance with 
the ICH E6 Guidelines on Good Clinical Practice. All sub-
jects signed an Institutional Review Board (IRB)/Independ-
ent Ethics Committee (IEC)-approved informed consent 
form before any study-specific procedures were performed.
Investigational product
ABP 980 was sourced from Amgen, Inc. (Thousand 
Oaks, CA, USA). Trastuzumab (US) was sourced from 
Genentech, Inc. (South San Francisco, CA, USA), and 
trastuzumab (EU) was sourced from Roche Pharma AG 
(Grenzach-Wyhlen, Germany). ABP 980 and trastuzumab 
(US) were supplied in vials containing 440 mg of investiga-
tional product, and trastuzumab (EU) was supplied in vials 
containing 150 mg of investigational product. All investiga-
tional products were reconstituted to 21 mg/mL. The pro-
tein content of each of the drug lots obtained by the clini-
cal sites was evaluated by Amgen, Inc. No adjustment to 
dosage was necessary as the differences in protein content 
between formulations were determined to be less than 5%.
Study design and subject population
This randomized, single-blind, single-dose, three-arm, par-
allel-group study in healthy adult males was conducted at a 
single center (Fig. 1). A total of 150 healthy male subjects 
were planned to be enrolled in the study.
Subjects were randomized in a ratio of 1:1:1, stratified 
by ethnicity (Japanese versus non-Japanese), to receive a 
single intravenous (IV) infusion of ABP 980 6 mg/kg, tras-
tuzumab (US) 6 mg/kg, or trastuzumab (EU) 6 mg/kg over 
90  min. Subjects, but not healthcare professionals admin-
istering the investigational product, were blinded to which 
treatment they were receiving.
Eligible participants included healthy adult men 
≥18–≤45  years of age. Inclusion criteria comprised nor-
mal or clinically acceptable physical examination, clinical 
laboratory test values, vital signs, echocardiogram, and 
electrocardiogram (ECGs) at screening, body mass index 
(BMI) ≥18.0 and ≤30.0  kg/m2 for non-Japanese subjects, 
and BMI ≥18.0 and ≤25.0  kg/m2 for Japanese subjects. 
Physical examination, ECGs, and vital signs were repeated 
on Day-1.
Exclusion criteria included men of reproductive poten-
tial unwilling to practice a highly effective method of birth 
control, or refrain from donating sperm, for the duration of 
the study and for 5  months after treatment and men with 
pregnant partners. Additional exclusion criteria included a 
history or evidence of a clinically significant disorder, con-
dition, or disease that could pose a risk to subject safety 
or interfere with the study; history or presence of condi-
tions known to interfere with the distribution, metabo-
lism, or excretion of drugs; history of surgery or major 
trauma within 12  weeks of screening, or surgery planned 
during the study; prior exposure to trastuzumab or related 
compounds; known or suspected sensitivity to products 
derived from mammalian cell lines; and subjects who were 
receiving or had received any investigational drug, device, 
or medication (prescription or over-the-counter) within 
30 days or 5 half-lives (whichever was longer) of receiving 
study medication.
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Subjects were screened and informed consent was 
obtained within 28 days of treatment administration. Day-1 
assessment included medical history, physical examina-
tion, vital signs, and body weight. Body weight on Day-1 
was used to calculate dose. Day 1 pre-dose procedures and 
assessments included vital signs and collection of samples 
for baseline assessment of hematology, chemistry, urinaly-
sis, and ADAs.
Subjects remained in the study center or clinical phar-
macology unit (CPU) for at least 24  h after dosing for 
safety and PK assessments. They were discharged on Day 
2 after the 24-h assessments were completed. Subjects 
returned to the CPU on Days 3, 5, 9, 15, 22, 29, 36, 43, 
and 50, and Day 64 [end-of-study (EOS) visit] for safety 
evaluations and PK assessments. Vital signs and laboratory 
measurement were taken on Days 1 and 64 (EOS).
Sampling
Blood samples for serum ABP 980 or trastuzumab concen-
tration determination were collected pre-dose, at 0.75 (mid-
infusion), 1.5 (end of infusion), 2, 3, 4, 5, 6, 8, and 24 h 
after the start of dosing, and at each return visit to the CPU. 
Blood sampling for PK analysis during each return visit to 
the CPU, including the EOS visit, occurred per the sched-
uled timepoint.
A validated electrochemiluminescence (ECL) assay 
was used to quantify serum concentrations of ABP 980 
and trastuzumab using a mouse anti-trastuzumab mono-
clonal anti-body (mAb) to capture the investigational 
product. After capturing ABP 980 or trastuzumab to the 
immobilized anti-body, unbound materials were removed, 
followed by the addition of ruthenium labeled mouse anti-
trastuzumab mAb to detect the captured ABP 980 or tras-
tuzumab. A tripropylamine buffer was added to enhance 
the electrochemiluminescent signals. The ECL counts were 
directly proportional to the amount of ABP 980 or trastu-
zumab bound by the capture reagent. Conversion of ECL 
counts to concentrations was performed using the Gen5™ 
Secure Software v1.08.
Safety and tolerability were reviewed by the medical 
monitor on an ongoing basis. Adverse events (AEs) were 
monitored throughout the study. All AEs and serious AEs 
(SAEs) were reported. Adverse events were coded using 
MedDRA Version 17.0.
Anti-drug anti-bodies assay
Binding and neutralizing ADAs were detected with a two-
tiered approach that included a screening assay and a con-
firmatory assay. Sampling for ADAs occurred on Day 1 
pre-dose and at the EOS visit. A validated immunoassay 
was used to detect anti-bodies capable of binding ABP 980, 
trastuzumab (US), or trastuzumab (EU). All samples posi-
tive for binding ADAs were assessed for neutralizing anti-
bodies capable of binding to ABP 980, trastuzumab (US), 
or trastuzumab (EU) using a target binding assay.
Study endpoints
The primary endpoints were  AUCinf and Cmax for ABP 
980, trastuzumab (US), and trastuzumab (EU). Secondary 
Fig. 1  Study design. CPU clinical pharmacology unit, EOS end of 
study, EU European Union, FDA Food and Drug Administration, 
IV intravenous, PK pharmacokinetic, US United States. aPlanned IV 
dose: ABP 980 6  mg/kg, 440  mg vial; FDA-licensed trastuzumab 
6  mg/kg, 440  mg vial; or EU-authorized trastuzumab 6  mg/kg, 
150 mg vial
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endpoints included terminal elimination half-life (t½); the 
time at which Cmax was observed (tmax); AUC from time 
0 to the last quantifiable concentration  (AUClast); and last 
measureable serum concentration (Clast) for ABP 980 and 
trastuzumab. Although  AUClast was not defined as a pri-
mary endpoint, to fully assess exposure to the investiga-
tional product,  AUClast was also statistically evaluated. Sec-
ondary safety and immunogenicity endpoints included the 
incidence of treatment-emergent AEs (TEAEs), SAEs, and 
ADAs.
Pharmacokinetic equivalence was established if the 90% 
confidence intervals (CIs) for the ratio of least square geo-
metric means (GMs) of primary PK parameters comparing 
ABP 980 versus trastuzumab (US), ABP 980 versus tras-
tuzumab (EU), and trastuzumab (US) versus trastuzumab 
(EU) fell within the standard equivalence criteria of 0.80 
and 1.25.
Statistical analysis
Serum trastuzumab and ABP 980 concentrations were 
listed and summarized descriptively by treatment and time-
point using the PK concentration population including all 
subjects who were randomized and received any amount of 
investigational product and had at least one reported serum 
concentration of ABP 980 or trastuzumab. Mean trastu-
zumab and ABP 980 serum concentration–time data by 
treatment were presented graphically on semi-logarithmic 
and linear scales.
PK parameters were calculated using non-compartmen-
tal techniques  (WinNonlin® Professional Network Edition, 
Version 6.3, Pharsight Corp, St. Louis, MO) for all sub-
jects. Prior to statistical modeling, PK parameters were 
 loge-transformed. Point estimates and 90% CIs for the mean 
difference in logarithmic PK parameters were estimated 
using an analysis of variance (ANOVA) model adjusted for 
treatment and ethnicity using the PK parameter population 
including all subjects with an evaluable ABP 980 or tras-
tuzumab serum concentration–time profile. The point 
estimates and 90% CIs for GM ratios (GMRs) were then 
calculated by transforming back to the original scale and 
PK similarity was established if the 90% CIs fell within the 
standard equivalence criteria of 0.80 and 1.25.
Safety analysis included descriptive summaries of AEs 
and the incidence of ADAs, using the safety population 




A total of 157 subjects were randomized to treatment with 
ABP 980 (n = 50), trastuzumab (US) (n = 52), and trastu-
zumab (EU) (n = 55); 148 (94.3%) subjects completed the 
study; 9 (5.7%) subjects [3 subjects in the trastuzumab 
(US) group and 6 subjects in the trastuzumab (EU) group] 
discontinued from the study prematurely. One subject in 
the trastuzumab (EU) group prematurely discontinued infu-
sion owing to an infusion reaction. This subject received a 
total volume infused of approximately 4.8 mg/kg and was 
excluded from the PK parameter and per protocol PK anal-
ysis. No subject had a medical or surgical history that pro-
hibited them from participation in the study. Subject demo-
graphics are summarized in Table 1. Age, height, weight, 
and BMI were similar across treatment groups. The major-
ity of subjects (62.4%) in the study were white.
Pharmacokinetic profiles
The mean serum concentration–time profiles were similar 
between treatments following a single 6 mg/kg IV infusion 
of ABP 980, trastuzumab (US), or trastuzumab (EU) over 
Table 1  Demographic data and 
baseline characteristics
BMI body mass index, SD standard deviation
ABP 980 (n = 50) Trastuzumab (US) 
(n = 52)
Trastuzumab 
(EU) (n = 55)
Mean age, years (SD) 25.8 (5.8) 25.4 (5.6) 25.6 (4.6)
Mean weight, kg (SD) 76.4 (11.1) 73.6 (10.8) 74.7 (11.8)
Mean height, cm (SD) 176.5 (6.25) 177.2 (7.37) 177.6 (8.01)
Mean BMI, kg/m2 (SD) 24.4 (2.8) 23.3 (2.5) 23.6 (3.4)
Race, n (%)
 Asian (1st generation Japanese) 10 (20.0) 10 (19.2) 11 (20.0)
 Asian (other) 8 (16.0) 6 (11.5) 5 (9.1)
 Black or African-American 3 (6.0) 0 0
 White 28 (56.0) 34 (65.4) 36 (65.5)
 Other 1 (2.0) 2 (3.8) 3 (5.5)
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the entire course of the study (Fig. 2). Peak concentrations 
were observed approximately 1.5–5 h after the start of the 
infusion with similar Cmax and tmax in all treatment groups.
Descriptive summary of PK parameters for ABP 980, 
trastuzumab (US), and trastuzumab (EU) is presented in 
Table  2. A total of 12 subjects [4 subjects in the trastu-
zumab (US) group and 8 subjects in the trastuzumab (EU) 
group] either terminated the study early or had multiple 
missing samples. These subjects were included in the PK 
Parameter Population, as Cmax and tmax were considered to 
have been sufficiently characterized before the early termi-
nation or missing samples; however,  AUCinf was consid-
ered non-evaluable in these subjects and was, therefore, 
excluded from analysis. The GMs of PK parameters were 
similar across treatment groups following a single IV infu-
sion of ABP 980, trastuzumab (US), and trastuzumab (EU) 
(Table  2). The GMs of Cmax and  AUCinf were 139.9  μg/
mL and 35,224  μg  h/mL for ABP 980; 134.6  μg/mL and 
33,342  μg  h/mL for trastuzumab (US); and 140.5  μg/mL 
and 35,123 μg h/mL for trastuzumab (EU). The terminal  t½ 
was estimated to be 6–7 days. For all subjects in each treat-
ment arm,  AUClast accounted for ≥90% of the total AUC, 
confirming the adequacy of the duration of PK sampling 
across the three treatments.
The results of the statistical assessment of PK similarity 
for the overall population are shown in Table 3. The GMRs 
and 90% CIs for Cmax and  AUCinf, respectively, were: 1.04 
(0.99–1.08) and 1.06 (1.00–1.12) for ABP 980 versus tras-
tuzumab (US); 0.99 (0.95–1.03) and 1.00 (0.95–1.06) for 
ABP 980 versus trastuzumab (EU); and 0.96 (0.92–1.00) 
and 0.95 (0.90–1.01) for trastuzumab (US) versus trastu-
zumab (EU). All comparisons were within the equivalence 
criteria of 0.80–1.25.
Safety results
Overall, the incidence of TEAEs was similar across treat-
ment groups. Treatment-emergent AEs were reported in 42 
(84.0%) subjects in the ABP 980 group, 39 (75.0%) subjects 
in the trastuzumab (US) group, and 43 (78.2%) subjects in 
the trastuzumab (EU) group. The majority of TEAEs were 
Fig. 2  Mean serum concentration–time profiles (PK concentration 
population) for ABP 980, trastuzumab (US), and trastuzumab (EU); 
linear scale (top) and expanded (0–16 h) scale (top inset); semi-loga-
rithmic scale (bottom).  Error bars SD
Table 2  Summary of 
pharmacokinetic parameters
GeoCV% geometric mean coefficient of variation, AUC area under the serum concentration–time curve, 
AUCinf AUC from time 0 extrapolated to infinity, AUClast AUC from time 0 to the last quantifiable concen-
tration, CI confidence interval, Cmax maximum serum concentration, LS least squares, tmax time at which 
the maximum serum concentration was observed, t½ terminal elimination half-life, Max maximum, Min 
minimum, SD standard deviation, GM geometric mean, n number of non-missing observations
Parameter ABP 980 Trastuzumab (US) Trastuzumab (EU)
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mild to moderate in severity. Treatment-related AEs (i.e., 
TEAEs assessed as possibly or probably related to study 
drug) were reported in 33 (66.0%), 33 (63.5%), and 39 
(70.9%) subjects in the ABP 980, trastuzumab (US), and 
trastuzumab (EU) groups, respectively.
There were no deaths or life-threatening TEAEs or 
TEAEs leading to study discontinuation. Two subjects 
reported TEAEs rated as severe; one subject in the trastu-
zumab (EU) group had an SAE of infusion-related reaction 
that was considered probably related to study drug; and one 
subject in the trastuzumab (US) group had multiple SAEs 
resulting from a motor bike accident, including pulmonary 
embolism secondary to deep vein thrombosis, not related to 
study medication. None of the SAEs resulted in premature 
study discontinuation.
The most frequently reported TEAEs (reported in 
>5% of subjects in any treatment group) were headache, 
upper respiratory tract infection, chills, pyrexia, myalgia, 
nausea, epistaxis, arthralgia, and lethargy (Table  4). No 
new or unexpected safety signals were identified, and the 
safety profiles were consistent with what is known for 
trastuzumab.
Anti-drug anti-bodies
Immunogenicity was assessed at baseline just prior to dos-
ing and at the EOS visit (Day 64). For all subjects, the con-
centrations of ABP 980 or trastuzumab at the end of the PK 
sampling period were well below the drug tolerance levels 
of 20 and 100 μg/mL in the presence of 100 and 500 ng/mL 
ADA, respectively, indicating that ADA detection was not 
influenced by circulating drug levels. There were no pre-
existing binding ADAs detected in baseline samples and no 
subjects had developed binding or neutralizing ADAs at the 
end of the study.
Table 3  Statistical assessment of pharmacokinetic parameters
Statistical model includes treatment and ethnicity as fixed effects
GM geometric means, LS least squares, n number of non-missing observations
PK parameters
Cmax (μg/mL)
Adjusted LS GM (n)
AUCinf (μg h/mL)
Adjusted LS GM (n)
AUClast (μg h/mL)
Adjusted LS GM (n)
ABP 980 135.9 (50) 34061.4 (50) 33811.7 (50)
Trastuzumab (US) 131.2 (52) 32271.7 (48) 32113.6 (48)
Trastuzumab (EU) 136.8 (54) 33947.0 (46) 33748.2 (46)
Statistical analysis: ratio and 90% CI of adjusted least square geometric means
 ABP 980 versus trastuzumab (US) 1.04 (0.9948–1.0787) 1.06 (0.9974–1.1169) 1.05 (0.9967–1.1122)
 ABP 980 versus trastuzumab (EU) 0.99 (0.9540–1.0338) 1.00 (0.9476–1.0624) 1.00 (0.9479–1.0589)
 Trastuzumab (US) vs trastuzumab (EU) 0.96 (0.9213–0.9975) 0.95 (0.8973–1.0072) 0.95 (0.8998–1.0063)
Table 4  Summary of treatment-emergent adverse events (safety population)
Adverse events were coded using MedDRA Version 17.0
A TEAE is defined as an AE that was not present prior to treatment with investigational product, but appeared following treatment or was pre-
sent at treatment initiation but worsened during treatment. Subjects with multiple events in the same category were counted only once in that 
category; subjects with events in more than 1 category were counted once in each of those categories
MedDRA preferred term ABP 980 (n = 50) Trastuzumab (US) (n = 52) Trastuzumab (EU) (n = 55)
n (%) No. of events n (%) No. of events n (%) No. of events
Headache 16 (32.0) 21 19 (36.5) 26 24 (43.6) 30
Upper respiratory tract infection 21 (42.0) 25 18 (34.6) 20 20 (36.4) 22
Chills 3 (6.0) 3 6 (11.5) 7 7 (12.7) 8
Pyrexia 3 (6.0) 3 5 (9.6) 5 8 (14.5) 8
Myalgia 8 (16.0) 8 3 (5.8) 3 1 (1.8) 1
Nausea 2 (4.0) 2 5 (9.6) 5 4 (7.3) 4
Epistaxis 3 (6.0) 4 3 (5.8) 3 3 (5.5) 3
Arthralgia 5 (10.0) 5 1 (1.9) 1 1 (1.8) 1
Lethargy 3 (6.0) 3 2 (3.8) 2 0 0
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Discussion
This study was conducted to determine the PK similar-
ity of the proposed biosimilar ABP 980 to trastuzumab. 
Study enrollment was restricted to healthy male subjects, 
because healthy subjects should provide the most homog-
enous population for sensitive comparisons of the PK of 
ABP 980 and trastuzumab. The dose and sampling sched-
ule chosen in this study were based on a previous study of 
trastuzumab [15]. A dose of 6  mg/kg provided sufficient 
exposure to study medication for an accurate evaluation of 
PK in healthy subjects within the dose range with linear 
kinetics and is, therefore, appropriate to detect potential PK 
differences between ABP 980, trastuzumab (US), and tras-
tuzumab (EU). A dose of 6 mg/kg is also consistent with 
the prescribing instructions for  Herceptin® [1, 2]. Based on 
t½ of 6–6.8 days in healthy males in a prior pilot study for 
ABP 980 and trastuzumab (EU), 64 days of PK sampling 
post-infusion was considered sufficient to fully character-
ize the ABP 980 or trastuzumab PK profiles in healthy 
subjects.
This study was conducted to meet FDA and EMA guide-
lines for the development and approval of biosimilar agents 
[10–13]. Both agencies recommend a stepwise develop-
mental approach designed to determine the similarity of the 
proposed biosimilar to the reference product with respect 
to physicochemical and functional characteristics, PK pro-
file, and clinical efficacy, safety, and tolerability. The ana-
lytical and functional similarity of ABP 980 to trastuzumab 
sourced from the USA and EU has been extensively stud-
ied, and the results have been reported previously [14]. 
ABP 980 was shown to be similar to trastuzumab (US) and 
trastuzumab (EU) with respect to primary and higher order 
structure, HER2 binding affinity, inhibition of proliferation, 
and in  vitro anti-body-dependent cell-mediated cytotoxic-
ity. The results of this study further support that ABP 980 
is similar to trastuzumab by demonstrating equivalence of 
ABP 980 to both trastuzumab (US) and trastuzumab (EU) 
with respect to PK profile.
A single 6  mg/kg IV infusion of ABP 980 in healthy 
male subjects resulted in a similar PK profile to both tras-
tuzumab (US) and trastuzumab (EU) with respect to the 
primary PK parameters of  AUCinf and Cmax. For both PK 
parameters, the 90% CIs were contained within the pre-
specified standard equivalence margin of 0.8–1.25. The 
safety and tolerability of ABP 980, trastuzumab (US), and 
trastuzumab (EU) also were comparable and consistent 
with what is known for trastuzumab. No new or unexpected 
safety signals were noted.
The study design used here also allowed a direct com-
parison between trastuzumab (US) and trastuzumab (EU). 
Direct comparison between reference products sourced 
from different regions also has important regulatory 
and clinical implications. Strong evidence for similarity 
between ABP 980 and trastuzumab, based on comprehen-
sive analytical and functional assessment, is necessary to 
support clinical studies and ultimately extrapolation to 
all approved trastuzumab indications [16, 17]. The FDA 
and EMA have each developed guidelines that allow the 
use of foreign-sourced reference products in comparative 
clinical trials provided that there is sufficient scientific 
evidence demonstrating similarity between the foreign-
sourced and locally-sourced reference products. In this 
three-arm study, the 90% CIs for  AUCinf and Cmax were 
within the equivalence margin of 0.8 to 1.25 for trastu-
zumab (US) versus trastuzumab (EU), hence established 
PK bioequivalence between USA-sourced trastuzumab 
and EU-sourced trastuzumab, which is a required compo-
nent to establish a scientific bridge between USA-sourced 
and EU-sourced trastuzumab, thus allowing use of one 
reference product in comparative Phase III clinical tri-
als. Safety and tolerability also were comparable between 
trastuzumab (US) versus trastuzumab (EU).
As with all biologic agents, the risk for developing 
binding or neutralizing ADAs must be carefully assessed. 
In this study, immunogenicity was evaluated by assaying 
blood samples for the presence of binding or neutralizing 
ABAs on Day 1 before infusion and at the end-of-study 
visit. No subject in any treatment arm developed ADAs. 
This finding is consistent with previous studies demon-
strating a low incidence of ADAs with trastuzumab [15, 
18].
In conclusion, in this Phase I study, there were no dif-
ferences between ABP 980, trastuzumab (US), and tras-
tuzumab (EU) with respect to PK profile, safety, and 
tolerability after a single IV infusion. No subject tested 
positive for binding ADAs. In addition to the results of 
structural and functional characterization, these results 
provide further support that the proposed biosimilar ABP 
980 is highly similar to FDA-licensed and EU-authorized 
trastuzumab reference products.
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